Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT

Research output: Contribution to journalArticlepeer-review

Abstract

We present the case of a 71-year-old man with Gleason 3 + 3 = 6 pT2N0MxR0 adenocarcinoma of the prostate who presented with rising PSA level 16 years after radical prostatectomy. PSMA-targeted 18F-DCFPyL PET/CT was performed, which demonstrated recurrent disease in the prostatectomy bed as well as splenomegaly and mild-diffuse bone marrow activation, consistent with the patient's history of hereditary spherocytosis. We briefly review the clinical characteristics of hereditary spherocytosis, its appearance on molecular imaging studies, the normal biodistribution of 18F-DCFPyL, and the PSMA-RADS scoring system for characterizing findings on PSMA-targeted PET imaging.

Original languageEnglish (US)
Pages (from-to)e313-e314
JournalClinical nuclear medicine
Volume44
Issue number4
DOIs
StatePublished - Apr 1 2019

Keywords

  • F-DCFPyL
  • PSMA-RADS
  • PSMA-targeted PET
  • hereditary spherocytosis
  • prostate cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted <sup>18</sup>F-DCFPyL PET/CT'. Together they form a unique fingerprint.

Cite this